Second chances for secondary AML.
作者信息
Appelbaum Jacob S, Appelbaum Frederick R, Percival Mary-Elizabeth
机构信息
Division of Hematology/Oncology, Department of Medicine, University of Washington, Seattle, WA.
Clinical Research Division, Fred Hutch Cancer Center, Seattle, WA.
出版信息
Blood Adv. 2024 Aug 13;8(15):4221-4222. doi: 10.1182/bloodadvances.2024013318.
Abstract
摘要
相似文献
1
Second chances for secondary AML.继发性急性髓系白血病的第二次机会
Blood Adv. 2024 Aug 13;8(15):4221-4222. doi: 10.1182/bloodadvances.2024013318.
2
Challenges in the diagnosis and treatment of secondary acute myeloid leukemia.继发性急性髓系白血病诊断与治疗的挑战。
Crit Rev Oncol Hematol. 2019 Jun;138:6-13. doi: 10.1016/j.critrevonc.2019.03.003. Epub 2019 Mar 16.
3
Acute Myeloid Leukemia Diagnosed 5 Years after Adult T-Cell Leukemia/Lymphoma.成人T细胞白血病/淋巴瘤确诊5年后诊断出急性髓系白血病。
J Clin Exp Hematop. 2015;55(1):29-31. doi: 10.3960/jslrt.55.29.
4
Development of acute myeloid leukemia in patients with untreated chronic lymphocytic leukemia.未经治疗的慢性淋巴细胞白血病患者发生急性髓系白血病。
Ann Hematol. 2017 May;96(5):719-724. doi: 10.1007/s00277-017-2933-x. Epub 2017 Feb 1.
5
Identification of novel gene fusion and personalized therapeutic targets through integrative clinical sequencing in secondary acute myeloid leukemia in a patient with severe congenital neutropenia: a case report and literature review.通过对一名严重先天性中性粒细胞减少症患者继发性急性髓系白血病进行综合临床测序鉴定新的基因融合和个性化治疗靶点：病例报告及文献综述
Cold Spring Harb Mol Case Stud. 2018 Apr 2;4(2). doi: 10.1101/mcs.a002204. Print 2018 Apr.
6
Secondary parotid mucoepidermoid carcinoma after TBI and chemotherapy in childhood AML.
Pediatr Blood Cancer. 2006 Sep;47(3):345-6. doi: 10.1002/pbc.20832.
7
Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?急性髓系白血病（AML）的晚期复发：克隆进化还是治疗相关白血病？
Blood Cancer J. 2019 Jan 16;9(2):7. doi: 10.1038/s41408-019-0170-3.
8
Secondary acute myeloid leukemia arising early after cyclophosphamide treatment.环磷酰胺治疗后早期发生的继发性急性髓系白血病。
Int J Clin Pharm. 2015 Apr;37(2):289-91. doi: 10.1007/s11096-015-0069-4. Epub 2015 Jan 23.
9
Lineage switch of B-lymphoblastic leukemia into acute myeloid leukemia with residual lymphoblasts in a patient with previous breast cancer.一名曾患乳腺癌的患者中，B淋巴细胞白血病向伴有残留淋巴母细胞的急性髓系白血病的谱系转换。
Int J Lab Hematol. 2021 Aug;43(4):O197-O199. doi: 10.1111/ijlh.13510. Epub 2021 Mar 14.
10
Outcome of patients aged 60-75 years with newly diagnosed secondary acute myeloid leukemia: A single-institution experience.60-75 岁新诊断继发性急性髓细胞白血病患者的结局：单中心经验。
Cancer Med. 2019 Jul;8(8):3846-3854. doi: 10.1002/cam4.2020. Epub 2019 Jun 7.
本文引用的文献
1
Haploidentical transplantation in primary refractory/relapsed secondary vs de novo AML: from the ALWP/EBMT.原发性难治/复发继发性 AML 与初发 AML 中 haploidentical 移植：来自 ALWP/EBMT。
Blood Adv. 2024 Aug 13;8(15):4223-4233. doi: 10.1182/bloodadvances.2024012798.
2
Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial.复发或反应不佳的急性髓系白血病患者的缓解诱导与立即进行异基因造血干细胞移植（ASAP）：一项随机、开放标签、3期、非劣效性试验。
Lancet Haematol. 2024 May;11(5):e324-e335. doi: 10.1016/S2352-3026(24)00065-6. Epub 2024 Apr 4.
3
Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience.维奈托克在复发或难治性急性髓系白血病患者中的应用：PETHEMA注册研究经验
Cancers (Basel). 2022 Mar 29;14(7):1734. doi: 10.3390/cancers14071734.
4
Naive T-Cell Depletion to Prevent Chronic Graft-Versus-Host Disease.采用幼稚 T 细胞耗竭预防慢性移植物抗宿主病。
J Clin Oncol. 2022 Apr 10;40(11):1174-1185. doi: 10.1200/JCO.21.01755. Epub 2022 Jan 10.
5
Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia.维奈托克联合 FLAG-IDA 诱导和巩固治疗新诊断和复发/难治性急性髓系白血病。
J Clin Oncol. 2021 Sep 1;39(25):2768-2778. doi: 10.1200/JCO.20.03736. Epub 2021 May 27.
6
IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy.白细胞介素-18 结合蛋白是一种分泌型免疫检查点和白细胞介素-18 免疫治疗的障碍。
Nature. 2020 Jul;583(7817):609-614. doi: 10.1038/s41586-020-2422-6. Epub 2020 Jun 24.
7
Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission.单倍体相合与同胞相合移植治疗急性髓系白血病完全缓解 1 期的结果。
Blood Adv. 2019 Jun 25;3(12):1826-1836. doi: 10.1182/bloodadvances.2019000050.
8
Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?异基因造血细胞移植治疗急性髓系白血病：是时候转向基于微小残留病的完全缓解定义了吗？
J Clin Oncol. 2016 Feb 1;34(4):329-36. doi: 10.1200/JCO.2015.63.3826. Epub 2015 Dec 14.
9
Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy.初治诱导治疗失败的新诊断急性髓系白血病患者的转归
Biol Blood Marrow Transplant. 2015 Mar;21(3):559-64. doi: 10.1016/j.bbmt.2014.10.025. Epub 2014 Dec 20.
10
International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia.依拉环素对比研究者选择的挽救治疗方案用于治疗复发/难治性急性髓系白血病的国际多中心 III 期随机研究。
J Clin Oncol. 2014 Jun 20;32(18):1919-26. doi: 10.1200/JCO.2013.52.8562. Epub 2014 May 19.
Zotero 插件